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Abstract By a systematic review and meta-analysis to
investigate clinically relevant effects of selenium supple-
mentation in patients with chronic autoimmune thyroiditis.
Controlled trials in adults (≥18 years) with autoimmune
thyroiditis, comparing selenium with or without levothyr-
oxine substitution, versus placebo and/or levothyroxine
substitution, were eligible for inclusion. Identiﬁed outcomes
were serum thyrotropin (thyroid stimulating hormone)
levels in LT4-untreated patients, thyroid ultrasound and
health-related quality of life. Eleven publications, covering
nine controlled trials, were included in the systematic
review. Random effects model meta-analyses were per-
formed in weighted mean difference for thyroid stimulating
hormone, ultrasound and health-related quality of life.
Quality of evidence was assessed per outcome, using
GRADE. Meta-analyses showed no change in thyroid sti-
mulating hormone, or improvements in health-related
quality of life or thyroid echogenicity (ultrasound),
between levothyroxine substitution-untreated patients
assigned to selenium supplementation or placebo. Three
trials found some improvement in wellbeing in patients
receiving levothyroxine substitution, but could not be syn-
thesized in a meta-analysis. The quality of evidence ranged
from very low to low for thyroid stimulating hormone as
well as ultrasound outcomes, and low to moderate for
health-related quality of life, and was generally downgraded
due to small sample sizes. We found no effect of selenium
supplementation on thyroid stimulating hormone, health-
related quality of life or thyroid ultrasound, in levothyroxine
substitution-untreated individuals, and sporadic evaluation
of clinically relevant outcomes in levothyroxine
substitution-treated patients. Future well-powered RCTs,
evaluating e.g. disease progression or health-related quality
of life, are warranted before determining the relevance of
selenium supplementation in autoimmune thyroiditis.
Keywords Chronic autoimmune thyroiditis ● Hashimoto’s
thyroiditis ● Selenium supplementation ● Thyroid hormones ●
Systematic review ● Meta-analysis ● Quality of life ● Thyroid
ultrasound
Introduction
Chronic autoimmune (AIT) or Hashimoto’s thyroiditis
affects 1–2 % of the population with increasing prevalence
with age and a female preponderance. In communities
replete in iodine intake, it is the predominant cause of
hypothyroidism [1, 2]. The etiology is multifactorial and
based on genetic susceptibility in a complex interaction with
numerous environmental triggers [3, 4], possibly including
selenium deﬁciency [5]. No cure exists, and the standard
treatment is life-long levothyroxine substitution (LT4) to
normalize circulating thyrotropin [thyroid stimulating hor-
mone (TSH)] levels. Recent insights suggest that LT4
cannot ensure a euthyroid state in all tissues simultaneously
[6], and a place for selenium supplementation in the
treatment of AIT has been much debated [7]. Selenium is an
essential micronutrient with a wide range of effects in, e.g.
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redox homeostasis, immunity, and thyroid hormone meta-
bolism [8]. Since 2002, a number of trials have investigated
the effects of selenium supplementation in AIT. In a meta-
analysis from 2010, based on four trials, [9], the authors
reported decrease in thyroid peroxidase autoantibody (TPO-
Ab) levels and improvement in well-being and/or mood,
after 3 months of selenium supplementation, as compared to
placebo. Similar conclusions were reached in another meta-
analysis from 2014, including nine trials [10]. Finally, a
Cochrane Collaboration systematic review from 2013, also
including four studies, [11] reached no conclusion regarding
effects on HRQL, and did not perform a meta-analysis of
change in TPO-Ab because of considerable heterogeneity
among the included studies. While TPO-Ab levels are
central to the diagnosis of AIT [12], their clinical impor-
tance is less clear once treatment is initiated. The GRADE
guidelines provide a framework for determining outcomes
of interest [13], and rate morbidity or disease remission as
crucial when evaluating treatment effects [13]. However,
none of these outcomes were reported in the previous sys-
tematic reviews [9–11]. Further, the safety of upper toler-
able selenium intake limits has been questioned [14],
underlining that supplementation should only be adminis-
tered to correct deﬁcits or on solid clinical indication.
Due to insufﬁcient trial evaluation of clinically relevant
outcomes, and in view of recent safety concerns, we
hypothesized that selenium supplementation does not cur-
rently have a place in the treatment of AIT, and tested this
hypothesis in a systematic review and meta-analysis.
Materials and methods
Criteria for considering studies for this review
● Type of participants Adults (≥18 years) with AIT
● Types of intervention Any dose of selenium supple-
mentation, alone or combined with LT4.
● Types of controls Placebo alone, placebo combined with
LT4, or no treatment.
● Types of outcomes Mortality, morbidity, disease pro-
gression and/or remission, LT4 dose, HRQL, thyroid
function, thyroid ultrasound (US), adverse effects.
● Types of studies Controlled trials.
Focused review question
Which effect does selenium supplementation have on the
clinical course of AIT.
Literature search
The following databases were searched the 23rd of Sep-
tember 2015: Medline (from inception until 23rd of Sep-
tember 2015), EMBASE (from 1974 until 22nd of
September 2015) and Cochrane Central Register of Con-
trolled Trials (CENTRAL) (from inception until 23rd of
September 2015).
Selection of studies
records were imported from PubMed, EMBASE and
CENTRAL into Covidence (Covidence systematic review
software, Veritas Health Innovation, Melbourne, Australia,
available at www.covidence.org) where duplicates were
removed. Two reviewers (KHW and JW) independently
screened the remaining records, ﬁrst by title and then by
abstracts, using the Covidence software platform. Differ-
ences of opinion were resolved by discussion and con-
sensus. The screening process was documented in a
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) () ﬂow chart of study selection.
Data extraction
For studies that fulﬁlled the inclusion criteria, two review
authors (JW, KW) independently extracted relevant popu-
lation and intervention characteristics onto a pre-designed
template. Where we may have had further questions
regarding one or more of the included trials, we sent an
email request to the corresponding author of the study.
Data synthesis
Data was extracted as means with standard deviations (SD).
Where data was presented as median with 95% conﬁdence
interval (CI), an SD was calculated using the formula
((HCI-LCI)/2/TINV(0.05; n − 1) * sqrt (n)), where HCI is
the highest value in the conﬁdence interval (CI), LCI the
lowest value of the CI, and n the sample size of the group
[15]. Where data was presented as median with interquartile
range (IQR), the median was used as a mean and a SD was
calculated by the formula IQR/1.35 [15]. Where data was
presented as median with range, SD was estimated to be one
quarter of the range [15]. One trial, reported in two pub-
lications [16, 17], had four arms [selenium vs. LT4 vs.
selenium + LT4 vs. placebo]. We included the selenium vs.
placebo arms in the meta-analyses for effects on thyroid
function in an LT4-untreated population. Meta-analyses in
weighted mean difference (WMD) were performed for TSH
using the follow-up scores at 3, 6 and 12 months,
improvement in thyroid echogencity at 3 and 6 months, and
for the generic HRQL instrument SF-36, using follow-up
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scores at 6 months. The SF-36 is a general health ques-
tionnaire divided into eight domains, covering different
aspects of physical and mental well-being [18]. The het-
erogeneity of the included studies was evaluated by the I2
statistics: 0–40 % might not be important; 30–60 % may
represent moderate heterogeneity; 50–90 % may represent
substantial heterogeneity; 75–100% considerable hetero-
geneity. The outcomes ‘reduction in thyroid volume’ and
‘improvement in HRQL using other instruments than SF-
36’, could not be assessed in meta-analyses due to insufﬁ-
cient data, and were assessed qualitatively.
Quality of evidence
Quality of evidence for each outcome and risk of bias for
each study was assessed independently by KHW, JW and a
local consultant, using the GRADE guidelines [19].
The meta-analyses were performed in a random effects
model using STATA version 13.1 (2013; Stata Corporation,
College Station, TX, USA).
The systematic review was registered at PROSPERO on
the 24th of August 2015. Registration number:
CRD42015025247.
Results
Search results
3366 records were identiﬁed in the Medline, EMBASE and
CENTRAL databases. The screening process is presented in
Fig. 1. One article was identiﬁed by one of the authors from
another source [20]. All records were imported into the
Covidence software platform and 276 duplicates were
removed. Two reviewers (JW and KW) independently
screened the remaining 3091 records. 3029 records were
excluded following title screening, leaving 62 records to be
screened by abstract. 33 records were excluded after
abstract screening, leaving 29 articles to be assessed in full-
text. Full-text evaluation was carried out independently by
two reviewers (KW, JW) except for one record, written in
Hungarian [21], which was translated by a colleague. We
excluded conference abstracts [22–26], records published in
Chinese [27], and studies among pregnant women [28, 29].
Furthermore, one study was excluded due to a wrong
comparator, because both intervention- and control groups
received selenium supplementation [30]. Four records were
excluded on the basis of wrong study design, being reviews
[9–11] or a case report [31]. Finally, ﬁve trials were
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excluded because they only investigated effects on thyroid
autoantibody levels [21, 32–35], which we disregarded in
this context. Throughout the screening process, differences
of opinion were resolved by discussion and consensus. In
total, eleven publications reporting data from nine trials
were included in the systematic review [16, 17, 20, 36–43].
In the meta-analysis on TSH, ﬁve publications were
excluded because the trial populations consisted of AIT
patients receiving LT4 therapy [16, 17, 36, 37, 43], and one
publication was excluded [16] because data from the same
trial population was reported in reference [40].
Systematic review
The eleven publications included from the search were
published between 2002 and 2015, and reported data from
nine trials in 679 individuals. Identiﬁed outcomes of
importance for patients and clinicians were TSH levels,
HRQL and thyroid volume and echogenicity, assessed by
US. Data on mortality, morbidity or disease remission were
not identiﬁed. The main data are summarized in Table 1. All
trials, with the exception of one from Brazil [43], were
conducted in Europe. All trials used placebo as a control,
except one [38] that used no treatment. Four trials, reported
in ﬁve publications, were double-blinded [20, 39, 40, 42,
43]. One was single-blinded (US investigators) [38]. Two
trials were described as blinded without speciﬁcation [17,
36], while the follow-up study by Gartner et al. [37] was
open-label, along with another trial [41]. In one trial, the
authors did not account for blinding [16].
Change in thyroid function
Two trials provided detailed information about changes in
thyroid function in LT4-untreated patients [15, 39]. Eskes
et al. [42] reported that 2 of 30 patients in the control and 2
of 31 patients in the intervention group, developed sub-
clinical hypothyroidism during the months of follow-up.
Pilli et al. [20] reported subclinical hypothyroidism in 2 of
20 patients in the control group vs. 2 of 40 patients in the
selenium groups. The difference between selenium and
control groups was not signiﬁcant (RR 0.72; 95 % CI
0.19–2.75, p= 0.63). The quality of evidence was assessed
as moderate (Tables 2 and 3). Further, ﬁve trials reported
TSH levels as a continuous outcome [20, 38, 40–42],
evaluated below in a meta-analysis. Meta-analyses for
effects on serum thyroxine or triiodothyronine could not be
performed due to heterogeneous reporting.
Change in HRQL
Five trials evaluated HRQL [16, 17, 20, 36, 42]. Two
double-blinded trials used the SF-36 form [20, 42], and both T
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Endocrine
reported no signiﬁcant changes following six [42] or twelve
[20] months of selenium supplementation in patients not
treated with LT4. Two studies used the SF-12 form and
found signiﬁcant improvement in well-being by 200 μg/d
sodium selenite for three months, as compared to placebo
[17, 36]. In both trials, selenium supplementation was
administered adjuvant to LT4, and results were reported as
the proportion of participants experiencing improvement.
Both studies were described as ‘blinded’, without specify-
ing if participants or investigators were blinded for inter-
vention. One trial reported “improvement of mood and
sleep and less fatigue” in 25/34 (73.5 %) participants in the
intervention group receiving 200 μg/d selenomethionine for
6 months, and “amelioration of behavior and tiredness” in
15/31 (48.4 %) participants in the placebo group [16]. The
authors did not specify the method used or whether the
study was blinded. The above three trials, assessing HRQL
in LT4-treated patients, have previously been synthesized in
a meta-analysis [9]. Therefore, lacking additional trials for
this patient group, we performed no meta-analysis for this
outcome. The quality of evidence was assessed as low in
LT4-treated patients, and moderate in LT4-untreated
patients (Tables 2 and 3).
Change from baseline in thyroid US
Of four trials, reported in ﬁve publications, evaluating US
[20, 36–38, 43], one trial enrolled LT4-treated [36], and two
enrolled LT4-untreated [20, 38] patients, respectively. The
fourth trial enrolled both patient groups. Among LT4-
treated patients, one trial found a higher proportion of
“improved echogenicity” after 3 [36] and 9 months [37] of
200 μg sodium selenite daily. Results were reported in two
separate publications [36, 37], and the assessment was
qualitative. In LT4-untreated patients, one trial reported no
change in echogenicity or thyroid volume after twelve
months of 80 or 160 μg of selenomethionine supplementa-
tion daily [20]. The other trial reported increased hypoe-
chogenicity in controls, as compared to the intervention
group, after 12 months of 80 μg sodium selenite daily [38].
Both trials evaluated echogenicity by ranging gray scale
pixels from black to white [15, 37], and their results are
synthesized below in a meta-analysis. The fourth trial,
including both patient groups, found no change in thyroid
volume or echogenicity, evaluated by gray scale pixels,
after 3 months of 200 μg selenomethionine daily [43].
Quality of evidence was assessed as low for thyroid volume
and very low for echogenicity (Tables 2 and 3).
Adverse effects
Five trials did not account for adverse effects [17, 36, 38,
41, 43]. Two trials reported no adverse effects [15, 40],
including no changes in blood glucose levels [20]. Eskes
et al. [42] reported two cases of hair loss, equally distributed
in the placebo and selenium groups, while Krysiak et al.
[39] reported two cases with complaints of nausea and
headache in the selenium group, and no adverse effects in
the placebo group. The difference in adverse effects
between selenium and control groups was not signiﬁcant
(RR 2.59; 95 % CI 0.27–24.65, p= 0.41). The quality of
evidence was assessed as moderate (Tables 2 and 3).
Table 2 GRADE evidence proﬁle
Quality assessment Quality of
evidence
Outcome (number of trials) Limitations Inconsistency Indirectness Imprecision Publication
bias
Reduction in thyroid volume assessed by
ultrasound (2)
Serious limitations No serious inconsistency No serious indirectness Serious imprecision
(small sample size)
Undetected ++Low
Improvement in thyroid ultrasound
echogenicity, LT4-untreated patients (2)
No serious limitations Serious inconsistency
(conﬂicting ﬁndings)
Serious indirectness
(surrogate outcome)
Serious imprecision
(small sample size)
Undetected +Very low
Improvement in thyroid ultrasound
echogenicity, LT4-treated patients (2)
Serious limitations Serious inconsistency
(conﬂicting ﬁndings)
Serious indirectness
(surrogate outcome)
Serious imprecision
(small sample size)
Undetected +Very low
Improvement in HRQL, SF-36 (2) No serious limitations No serious inconsistency No serious indirectness Serious imprecision
(small sample size)
Undetected ++
+Moderate
Improvement in HRQL,
other instruments (3)
Serious limitations
(unclear blinding)
No serious inconsistency No serious indirectness Serious imprecision
(small sample size)
Undetected ++Low
Change in thyroid function (2)a No serious limitations No serious inconsistency No serious indirectness Serious imprecision
(small sample size)
Undetected ++
+Moderate
TSH at 3 months (4) No serious limitations No serious inconsistency Serious indirectness
(surrogate outcome)
Serious imprecision
(overall CI across 0)
Undetected ++Low
TSH at 6 months (5) No serious limitations No serious inconsistency Serious indirectness
(surrogate outcome)
Serious imprecision
(overall CI across 0)
Undetected ++Low
TSH at 12 months (2) No serious limitations Serious inconsistency
(heterogeneity)
Serious indirectness
(surrogate outcome)
Serious imprecision
(overall CI across 0)
Undetected +Very low
Adverse effects (4) No serious limitations No serious inconsistency No serious indirectness Serious imprecision
(small sample size)
Undetected ++
+Moderate
a Deﬁned as the development of hypothyroidism during the course of a trial
Endocrine
Meta-analysis
Change in TSH level
Compared to control groups, there was no signiﬁcant
change in TSH levels following selenium supplementation
in LT4-untreated populations after three months (four trials,
WMD: −0.09, 95 % CI −0.31–0.13, p= 0.42, I2= 0.0 %), 6
months (ﬁve trials, WMD: −0.03 95 % CI −0.24–0.18, p=
0.80, I2= 0.0 %), or 12 months (two trials, WMD 0.67, 95
% CI −0.27–1.62, p= 0.16, I2= 76.0 %). Results are
illustrated in Fig. 2. The quality of evidence was assessed as
low at 3 and 6 months, and very low at 12 months (Tables 2
and 3).
Change in HRQL (SF-36)
Compared to control groups, there were no signiﬁcant
changes in any of the eight SF-36 domains following 6
months of selenium supplementation in two trials enrolling
LT4-untreated individuals (data not shown) [20, 42].
The quality of evidence was assessed as moderate (Tables 2
and 3)
Change in thyroid echogenicity
Compared to control groups, there were no signiﬁcant
improvements in thyroid echogenicity following six (two
trials, WMD 2.88, 95 % CI −4.50–10.25, p= 0.45, I2=
57.7 %) or twelve (two, trials, WMD 1.92, 95 % CI:
−4.22–8.06, p= 0.54, I2= 46.5 %) months of selenium
supplementation in two trials enrolling LT4-untreated
individuals [20, 38]. The quality of evidence was assessed
as very low (Tables 2 and 3)
Quality of evidence assessment
Quality of evidence was assessed per outcome (Tables 2
and 3), using the GRADE guidelines [19]. For outcomes not
evaluated in meta-analyses, inconsistency was assessed by
comparing trial ﬁndings. Thyroid echogenicity and TSH
levels were downgraded for indirectness, since we deemed
these outcomes surrogate markers of lymphocytic inﬁltra-
tion and disease progression, respectively [13]. Egger’s test
(funnel plot) could not be performed, since none of our
meta-analyses contained ten studies or more [15]. However,
assessing if smaller trials were more prone to reporting
positive results than larger ones, showed no sign of pub-
lication bias.
Table 3 Risk of bias of included trials
Pilli 20151 [18] ? + + ? + +? –
De Farias 20152 [44] + + + + + +
–
Eskes 2014 [43] + + + + + +
Anastasilakis 2012 [42] – – – + + +
Krysiak 2012 [41] + + + + + +
Krysiak 2011 [40] + + + + + +
Nacamulli 20103 [39] ? ? ? ? + +
–
Karanikas 20084 [38] ? ? ? ? + ?
–
Duntas 20035 [37] ? ? ? ? + ?
– –
Gartner 2003 [36] ? ? – + + ?
Gartner 20026 [35] ? ? ? ? + ?
– –
+ = Low risk of bias
? = Unclear risk of bias
– = High risk of bias
R
andom
 sequence generation
A
llocation concealm
ent
Blinding
Incom
plete outcom
e data
Selective outcom
e reporting
O
ther bias
1 Blinding: Unclear risk of bias for ultrasound outcomes, low risk of
bias for other outcomes; Selective outcome reporting:
2 Selective outcome reporting: High risk of bias for ultrasound
outcomes (incomplete outcome reporting, including missing account
for disease duration, cannot be analyzed in a meta-analysis); Low risk
of bias for other outcomes
3 Selective outcome reporting: High risk of bias for ultrasound
outcomes, because thyroid volume as assessed by thyroid ultrasound
was described in methods, but the results are not reported
4 Selective outcome reporting: high risk of bias for Quality of Life
outcome, incomplete data reporting (cannot be analyzed in a meta-
analysis); Low risk of bias for other outcomes. Other bias: High risk of
bias for Quality of Life outcome (unknown outcome measure), unclear
risk (unclear source of funding)
5 Selective outcome reporting: high risk of bias for Quality of Life
outcome, incomplete data reporting (cannot be analyzed in a meta-
analysis); Low risk of bias for other outcomes
6 Selective outcome reporting: High risk of bias for Quality of Life and
ultrasound outcomes (incomplete outcome reporting, cannot be
analyzed in a meta-analysis), low risk of bias for other outcomes.
Other bias: High risk of bias for assessment of thyroid echogenicity,
which was done qualitatively
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Discussion
A key aspect in our evaluation of the nine included trials
was the division into populations of LT4-treated and
-untreated patients. This was done, according to GRADE
recommendations [13], because the outcomes deemed
important a priori were different in the respective popula-
tions. Three of the included trials enrolled patients receiving
LT4 [16, 17, 36], four trials dealt exclusively with untreated
patients [20, 38, 39, 42], and two trials included both
untreated and treated patients [41, 43].
In the three trials where selenium was administered
adjuvant to LT4, thyroid function could not readily be
assessed as an outcome due to the impact of LT4 per se.
Mortality, morbidity and disease remission are rated as
crucial according to the GRADE recommendations, and of
obvious concern, since hypothyroidism is associated with
increased somatic [44] and psychiatric morbidity [45], as
well as excess mortality [46]. However, these endpoints are
relatively infrequent, occur over longer periods of time [13],
and were not assessed in any of the identiﬁed trials. LT4
dose and/or HRQL constitute more readily assessable
relevant outcomes. No previous trials reported LT4 dose as
an outcome, but data on HRQL [33, 35, 36] have previously
been synthesized into meta-analyses [9, 10]. One reported
that patients assigned to selenium supplementation experi-
enced improved well-being or mood, as compared with
controls [9], and the other study showed no change [10].
However, neither of the previous reviews assessed the
quality of evidence, which we consider to be low due to
unclear blinding in relation to this subjective outcome.
Furthermore, none used a validated HRQL instrument for
hypothyroid patients, such as the ThyPRO [47, 48]. By
assessment with this instrument we have demonstrated
widely impaired HRQL, that is not normalized following
six months of LT4 treatment [49]. Finally, independent
effects on thyroid morphology, on top of the well-known
effects of LT4 on thyroid size [50], are difﬁcult to assess in
this group because the trials [36, 43] did not account for
disease duration.
In the LT4-untreated population, we prioritized disease
progression as the most important outcome. It can be
evaluated categorically by the proportion of patients
developing subclinical or overt hypothyroidism during the
time of intervention or follow-up. Two studies reported
direct data for this aspect [20, 42], showing no effect. In
addition, our meta-analysis for effects on TSH levels,
reached the same conclusion. Two trials assessed HRQL
effects [20, 42], and we found no signiﬁcant effects in a
meta-analysis on any SF-36 domains. While HRQL is
always an outcome of some importance, it might be of
limited relevance in untreated euthyroid patients, who are
more likely to be unaffected than are hypothyroid treated
patients. Two trials also investigated thyroid volume and
Fig. 2 Meta-analysis of the
effect of selenium
supplementation on serum
thyrotropin (thyroid simulating
hormone) levels in populations
of chronic AIT patients not
receiving LT4. Weighted mean
difference (WMD) in serum
TSH levels after 3, 6 and 12
months’ selenium
supplementation vs. control in
populations of AIT patients not
receiving LT4. Boxes represent
mean values of the outcomes in
a study, horizontal lines the
95 % conﬁdence intervals, and
the box area is proportional to
the weight of the individual
study (as seen in “Weight”).
Diamonds represent the overall
summary estimate, with
conﬁdence interval given by its
width. I2 shows the
heterogeneity among studies,
and with p-value
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echogenicity quantitatively [20, 38]. The studies yielded
contradictory results for echogenicity, but when synthesized
in a meta-analysis, the studies showed no effect.
Selenium supplementation did not signiﬁcantly impact
the incidence of adverse effects, which were reported only
in two double-blinded trials [39, 42]. Evaluation of long-
term morbidity following trial participation, would address
recently voiced safety concerns [14], e.g. regarding the
implications of selenium supplementation for glucose
metabolism. This issue was evaluated in only one trial and
found blood glucose levels unaltered [20].
Interestingly, direct clinical outcomes have been assessed
in another thyroid patient group. In a randomized placebo-
controlled trial, 169 euthyroid TPO-Ab positive pregnant
women were allocated to 200 μg/d selenomethionine or
matching placebo from 12 weeks gestation to 12 months
after delivery [28]. Post partum thyroid dysfunction and
permanent hypothyroidism were signiﬁcantly less prevalent
in patients receiving selenium, as compared to placebo.
Based on this, the authors concluded that selenium sup-
plementation reduced thyroid inﬂammatory activity and the
incidence of hypothyroidism in the post partum phase [28].
Seven of the included nine trials reported selenium status
in their patients. Six European trial populations [15, 33, 35,
36, 38, 39] were within a narrow range (70–85 μg/L) of
baseline serum/plasma selenium concentrations, while it
was lower (37 μg/L) in the Brazilian trial [40]. The current
selenium reference range is 100–120 μg/L [51], implying
marginal selenium deﬁciency in the European and more
marked deﬁciency in the Brazilian participants. The nine
identiﬁed trials intervened with 80–200 μg/day, using dif-
ferent formulations with varying bioavailablity; the
absorption of selenite is approximately 2/3 of the absorption
of selenomethionine [52]. In a recent narrative review it was
suggested that selenomethionine might be more effective
than selenite in lowering thyroid autoantibody levels [53].
However, no such trends were observed for any of the
clinical outcomes assessed in our study. The duration of
intervention exceeded six months only in two trials [20, 38].
Just in one trial [20] did selenium levels at the end of
intervention exceed the reference range, and in the Brazilian
trial [43], the plasma selenium concentration in the inter-
vention group increased only to 63.4 μg/L. Thus, trial
ﬁndings should mainly be interpreted in relation to cor-
recting marginal deﬁcits, rather than administering supra-
nutrional doses.
There are limitations to our study, and while the GRADE
approach rates the quality of evidence systematically, it
does not eliminate judgment [54], which is a limitation
per se. A statistical source of error is that one study pre-
sented data in median with IQR [20] and another in median
with range [42], both of which may be unreliable for cal-
culating a mean and a SD for the meta-analysis [20].
However, excluding these studies [20, 42] had no inﬂuence
on the results. Finally, the meta-analysis were performed
on the basis on very few studies, limiting the quality of the
evidence.
Future trials of selenium supplementation in AIT should
pay close attention to the selenium status of the study
populations, and identify outcomes of clinical importance
relating to the eligibility criteria set for trial participants. In
euthyroid individuals, whose tolerance to TPO or thyr-
oglobulin is broken, but where clinical disease is absent, we
recommend disease progression as an important outcome.
However, we found no effects on TSH level, which may be
considered as a surrogate marker, or on HRQL or thyroid
echogenicity. In hypothyroid patients, a rigorous trial
investigating LT4-dose titration as an outcome could
unmask implications for disease remission. Finally,
although the quality of evidence is low, previous trial results
give some promise of beneﬁcial effects on HRQL. This
outcome can now be evaluated using validated disease-
speciﬁc instruments [47, 48, 55], one of which (ThyPRO) is
the primary outcome in an ongoing trial [56].
There have been conﬂicting reports as to whether sele-
nium supplementation is of beneﬁt in patients with AIT
[53]. Our conclusion is that current evidence does not jus-
tify the emerging use of selenium supplementation in the
treatment of AIT [57]. While the correction of a selenium
deﬁcit may offer other health beneﬁts [8], routine selenium
supplementationin AIT patients should, at present, be dis-
couraged [58].
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